Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Artiva Biotherapeutics (ARTV) EBITDA: 2023-2024

Historic EBITDA for Artiva Biotherapeutics (ARTV) over the last 2 years, with Dec 2024 value amounting to -$16.6 million.

  • Artiva Biotherapeutics' EBITDA fell 38.47% to -$16.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$65.8 million, marking a year-over-year change of. This contributed to the annual value of -$65.8 million for FY2024, which is 131.63% down from last year.
  • Latest data reveals that Artiva Biotherapeutics reported EBITDA of -$16.6 million as of Q4 2024, which was up 4.02% from -$17.3 million recorded in Q3 2024.
  • Artiva Biotherapeutics' EBITDA's 5-year high stood at $11.4 million during Q3 2023, with a 5-year trough of -$17.9 million in Q2 2024.
  • For the 2-year period, Artiva Biotherapeutics' EBITDA averaged around -$11.9 million, with its median value being -$16.6 million (2024).
  • Data for Artiva Biotherapeutics' EBITDA shows a maximum YoY plummeted of 251.05% (in 2024) over the last 5 years.
  • Artiva Biotherapeutics' EBITDA (Quarterly) stood at -$12.0 million in 2023, then crashed by 38.47% to -$16.6 million in 2024.
  • Its EBITDA stands at -$16.6 million for Q4 2024, versus -$17.3 million for Q3 2024 and -$17.9 million for Q2 2024.